Literature DB >> 21364225

Rhinovirus infections in the upper airway.

Birgit Winther1.   

Abstract

The majority of cold and flulike illnesses are caused by human rhinoviruses (HRVs). Improved detection of HRV has shown that HRVs are also associated with more serious illness, such as exacerbation of asthma, wheezing illnesses in children, chronic obstructive pulmonary disease, cardiopulmonary disease, and fatal pneumonia in immune-compromised patients. HRV is a major cause of acute viral respiratory tract infections in hospitalized children and is among the leading causes of childhood mortality worldwide. Detection of the HRV genome by reverse transcriptase-polymerase chain reaction and genomic sequencing has brought to light a new clade, HRV-C, to the already recognized HRV-A and HRV-B clades. The clinical complications related to all rhinovirus infections include acute otitis media, acute sinusitis, and acute bronchitis. The enormous public health implications from those diseases far overshadow those of the common cold. This article provides an overview of the pathogenesis of rhinovirus infection in the upper airways. Most research has been done in young healthy adults with self-limiting experimental and natural rhinovirus infections, and this may set the stage for understanding rhinovirus infections in the ear, sinus, and lower airways.

Entities:  

Mesh:

Year:  2011        PMID: 21364225     DOI: 10.1513/pats.201006-039RN

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN: 1546-3222


  31 in total

1.  Multiple classes of antiviral agents exhibit in vitro activity against human rhinovirus type C.

Authors:  Chris Mello; Esmeralda Aguayo; Madeleine Rodriguez; Gary Lee; Robert Jordan; Tomas Cihlar; Gabriel Birkus
Journal:  Antimicrob Agents Chemother       Date:  2013-12-23       Impact factor: 5.191

2.  Severity of human rhinovirus infection in immunocompromised adults is similar to that of 2009 H1N1 influenza.

Authors:  Colleen S Kraft; Jesse T Jacob; Marti H Sears; Eileen M Burd; Angela M Caliendo; G Marshall Lyon
Journal:  J Clin Microbiol       Date:  2012-01-11       Impact factor: 5.948

Review 3.  Human rhinoviruses.

Authors:  Samantha E Jacobs; Daryl M Lamson; Kirsten St George; Thomas J Walsh
Journal:  Clin Microbiol Rev       Date:  2013-01       Impact factor: 26.132

4.  Acute bacterial sinusitis complicating viral upper respiratory tract infection in young children.

Authors:  Tal Marom; Pedro E Alvarez-Fernandez; Kristofer Jennings; Janak A Patel; David P McCormick; Tasnee Chonmaitree
Journal:  Pediatr Infect Dis J       Date:  2014-08       Impact factor: 2.129

5.  Nontypeable Haemophilus influenzae Type IV Pilus Mediates Augmented Adherence to Rhinovirus-Infected Human Airway Epithelial Cells.

Authors:  Stephen L Toone; Michelle Ratkiewicz; Laura A Novotny; Binh L Phong; Lauren O Bakaletz
Journal:  Infect Immun       Date:  2020-08-19       Impact factor: 3.441

6.  Quercetin inhibits rhinovirus replication in vitro and in vivo.

Authors:  Shyamala Ganesan; Andrea N Faris; Adam T Comstock; Qiong Wang; Suparna Nanua; Marc B Hershenson; Uma S Sajjan
Journal:  Antiviral Res       Date:  2012-03-23       Impact factor: 5.970

Review 7.  Environmental factors affecting the transmission of respiratory viruses.

Authors:  Natalie Pica; Nicole M Bouvier
Journal:  Curr Opin Virol       Date:  2012-01-04       Impact factor: 7.090

8.  Productive entry pathways of human rhinoviruses.

Authors:  Renate Fuchs; Dieter Blaas
Journal:  Adv Virol       Date:  2012-11-26

9.  Prescription surveillance and polymerase chain reaction testing to identify pathogens during outbreaks of infection.

Authors:  Hiroaki Sugiura; Tsuguto Fujimoto; Tamie Sugawara; Nozomu Hanaoka; Masami Konagaya; Kiyoshi Kikuchi; Eisuke Hanada; Nobuhiko Okabe; Yasushi Ohkusa
Journal:  Biomed Res Int       Date:  2013-02-07       Impact factor: 3.411

10.  The role of interleukin-1 and interleukin-18 in pro-inflammatory and anti-viral responses to rhinovirus in primary bronchial epithelial cells.

Authors:  Siân C Piper; John Ferguson; Linda Kay; Lisa C Parker; Ian Sabroe; Matthew A Sleeman; Emmanuel Briend; Donna K Finch
Journal:  PLoS One       Date:  2013-05-28       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.